Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Running, not enrolling · Phase 2

Conditions studied: BRAF V600E Mutation Present, Papillary Craniopharyngioma

In brief

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key facts

Study ID
NCT03224767
Run by
Alliance for Clinical Trials in Oncology
People needed
24
Starts
2018-01-05
Expected to finish
2028-08-01
Last updated by the study team
2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.